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Abstract: Marine organisms represent a highly diverse reserve of bioactives which could aid in the
treatment of a wide range of diseases, including various musculoskeletal conditions. Osteoporosis
in particular would benefit from a novel and effective marine-based treatment, due to its large
disease burden and the inefficiencies of current treatment options. Osteogenic bioactives have been
isolated from many marine organisms, including nacre powder derived from molluscan shells and
fucoidan—the sulphated polysaccharide commonly sourced from brown macroalgae. Such extracts
and compounds are known to have a range of osteogenic effects, including stimulation of osteoblast
activity and mineralisation, as well as suppression of osteoclast resorption. This review describes
currently known soluble osteogenic extracts and compounds from marine invertebrates and algae,
and assesses their preclinical potential.
Keywords: marine; bioactive; compound; extract; bone; bone growth; bone healing; osteoporosis;
algae; nacre
1. Introduction
Globally, an osteoporosis-related fracture occurs once every 3 seconds [1], whilst in Europe the
disease burden exceeds that of common neoplastic disorders, excluding lung cancer [1]. Osteoporosis
is linked to abnormal functioning of the basic multicellular unit (BMU); with decreased bone formation
by osteoblasts and increased resorption by osteoclasts, meaning bone is weaker and more susceptible to
fracture damage [2–4]. Fractures tend to affect people in their fourth or fifth decade of life, particularly
postmenopausal women, are often painful [5] and slow to heal, and present a large healthcare
burden [6]. Current treatment options are limited, having issues with their efficacy and long-term use.
For example, the antiresorptive drugs, bisphosphonates, are effective at reducing fracture risk [7,8],
but only promote small increases in bone density (<2%) [9] and have a number of rare but severe side
effects [10]. Anabolic agents, which increase bone growth, are even more limited—with teriparatide
the only clinically available treatment option. However, teriparatide requires daily administration
and is very costly, with positive effects quickly lost after ceasing treatment [10,11]. As such, there is a
need for new and efficacious treatment options, able to stimulate the recovery of bone density and
structure. Additionally, there are a number of other conditions, such as complex fracture and malunion,
that would also benefit from this [12].
Treatment for bone defects is highly variable, though in general bone regenerative medicine has
a triad of key features required for healing: a cellular component, a scaffold for tissue growth, and
the inclusion of bioactive/growth factors [13]. Excluding the cellular component, marine organisms
are a potential source of scaffold material and novel osteogenic (promoting new osteoblast bone
formation) bioactives. Scaffolds and other marine structural components used in tissue engineering
are beyond the scope of this review, though show significant promise and have been included in other
comprehensive reviews [14,15]. Instead, this work will detail bioactives derived from a diverse range
Mar. Drugs 2018, 16, 340; doi:10.3390/md16090340 www.mdpi.com/journal/marinedrugs
Mar. Drugs 2018, 16, 340 2 of 16
of marine taxa. These organisms produce bioactives through specialisation and adaptation, driven by
the challenge of living in environments such as the littoral zone [16,17]; with its extremes of variables
such as light, nutrient and temperature levels. Typically, marine environments are less well studied
than their terrestrial counterparts [16,18], likely due to the time and cost implications of exploratory
work [19]. However, there are examples of marine-derived osteogenic compounds/molecules that
show excellent clinical potential [20], and work in this area is continually developing—justifying an
up-to-date review of this field.
The aim of this review is to summarise the current marine organism-derived bioactives with
osteogenic potential. It will include discussion of invertebrate and alga-derived material (which show
particular promise), but will exclude bioactives from marine vertebrates such as fish (see Table 1 and
Figure 1 for summary of extracts included). Challenges to undertaking this work and sourcing marine
bioactives will also be discussed, as will future recommendations for the field.
Table 1. Summary table showing the genus, species, general description, and extract type of key
invertebrates that have been tested for their osteogenic effect in cell culture or relevant in vivo models.
This demonstrates the range of taxa investigated within this field, which are also referred to in the text.
Genus and Species General Description Extract/Bioactive Reference Example
Numerous assorted species Brown algae Fucoidan [21]
Numerous assorted species Brown algae Fucoidan (low molecular weight) [22]
Numerous assorted species Brown seaweed Fucoxanthin [23]
Sargassum horneri Brown algae Raw extract [24]
Sargassum siliquastrum Brown algae Sargachromanol G [25]
Sargassum thunbergii Brown algae Quinone derivatives [26]
Hizikia fusiforme Brown algae Water by-product [27]
Cladophora rupestris Green algae Crude extract [28]
Codium fragile Green algae Crude extract [28]
Laurencia undulata Red algae Floridoside [29]
Lithothamnion corallioides Calcareous red algae Aquamin [30]
Lyngbya sp. Cyanobacteria Macrolide [31]
Symbiodinium sp. Dinoflagellate Symbioimine [32]
Amphidinium sp. Dinoflagellate Polyketide [33]
Nannochloropsis oculata Microalgae Peptide [34]
Alteromonas infernus Prokaryote Polysaccharide [35]
Symploca sp. Cyanobacterium Largazole (depsipeptide) [36]
Phorbas sp. Sponge Phorbaketal A [37]
Zoanthus sp. Zoanthid Norzoanthamine [38]
Millepora dichotoma Hydrocoral Bioactive material [39]
Porites lutea Stony coral Bioactive material [40]
Porites lutea Stony coral Biomatrix [40]
Synularia polydactyla Alcyonarian coral Proteins [41]
Xenia elongate Soft coral Coral cells [42]
Montipora digitata Hard coral Coral cells [42]
Apostichopus japonicus Sea cucumber Fucan sulphate [43]
Haliotis discus hannai Abalone Digested intestines [44]
Haliotis laevigata Abalone Perlucin protein [45]
Numerous assorted species Mussels Adhesive protein [46]
Crassostrea gigas Oyster ProteinNacre (water soluble matrix) [47]
Pinctada maxima Pearl oyster Individual proteinsLow molecular weight molecules. [48]
Pteria martensii Pearl oyster Nacre (water soluble matrix) [49]
Pinctada margaritifera Oyster
Proteinase inhibitor
Proteins
Nacre (water soluble matrix)
[50]
Pinctada fucata Akoya pearl oyster Pinctada fucata mantle gene 3Protein p10 and other novel proteins [51]
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with osteogenic activity. Two groups are included—calcareous based extracts (nacre and maerl) and
organic extracts, which contains three main groups: assorted proteins, polysaccharides, and whole
algae extracts.
2. Mollusca
The phylum Mollusca is made up of eight distinct classes and is highly diverse, though as
of yet <1% of species have seen secondary metabolite investigation [52]—whilst testing of other
compounds/molecules is similarly limited. Within this, proteins, lipids, and carbohydrates have
seen particular research focus, with mussel lipids a w ll-established treatment f r rheumatoid
arthr tis [53]. In erms of osteogenic bioactives, novel activity h s been found—such as from
abalo e gastro-intestinal digests of Haliotis discus hannai. These parti lly digested extr ct were
investigated using an osteoblast-like cell line (MG-63), and subsequently were shown to increase
alkaline phosphatase (ALP) and mineralisation levels [44]. RT-PCR and Western blot analysis found
increased BMP-2 expression, thought to be a result of MAPK pathway activation. However, with the
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exception of this example, tests on nacre make up the majority of studies reporting osteogenic activity
from molluscan derived material.
Nacre
Nacre, often in its powdered form, features in a considerable body of research. Also known as
mother of pearl, nacre is the lustrous aragonitic inner layer found on molluscan shells in taxa such as
mussels and abalone. Like bone, nacre has both inorganic and organic components, with an organic
shell matrix comprised of proteins, glycoproteins and polysaccharides which then serve as a template
for calcium carbonate mineralisation [54]. It is this similarity that fuelled the idea that factors able to
stimulate mineralisation and support healthy human bone may be contained within nacre.
Research on nacre has been conducted since the early 1990s, with initial in vitro work
demonstrating its capacity to stimulate the mineralisation of human osteoblasts [55]. The most
interesting of these early studies investigated the ability of nacre to aid bone reconstruction in human
maxillary defects [56]. Here, nacre powder was mixed with the blood of patients and injected into the
defect site of eight middle-aged female patients. The results showed no evidence of toxic effect and
demonstrated enhanced mineralisation and good bio-dissolution of nacre within the area of injection.
The significance of this discovery was not realised until a subsequent commentary was published [57],
emphasising the remarkable ability of a raw and unrefined natural product to promote bone growth.
Since this early work, there has been a surge of research effort, including in vitro and in vivo studies,
as well as those specifically focusing on the proteins and mechanisms involved in enhancing cellular
activity, making nacre an excellent case study of bioactive research.
A good example of the in vitro work conducted used water soluble matrix (WSM) extracted
from the oyster Pinctada fucata [58]. This study demonstrated both the ability of nacre to enhance
osteoblast differentiation (increased Col-I, osteocalcin, and ALP expression) and its ability to scavenge
free radicals, suggesting an antioxidant potential that may also support bone regeneration. WSM has
also been shown to increase bone mineral density (BMD) in an ovariectomized mouse model of
osteoporosis [49], in part attributed to increased Runx2 and Fos-related antigen-1 expression as a result
of JNK pathway stimulation in osteoblasts. Furthermore, the extract suppressed actin ring formation
and RANKL-induced upregulation of c-Fos and NFATc1 in osteoclasts. Other in vivo work showed
nacre implanted into rat femurs supported new bone formation, implant/bone fusion, and increased
expression of numerous markers indicative of increased BMU action [59].
As the osteogenic potential of nacre is well established numerous studies have worked toward
identifying active components within the extract. At a basic level, nacre WSM can be broken down
into a number of fractions containing amino acids of varying size and composition [48]. Moreover,
numerous proteins have been identified within the nacre of different species, many of which are
thought to have roles in regulating bone tissue. For example, proteomic nacre analysis of the oyster
Crassostrea gigas found four novel proteins thought to aid in shell mineralisation, with structures
homologous to endogenous human proteins and with roles in osteogenesis [47]. Novel single
proteins, such as p10 [60], P60 [51], and PFMG3 [61], have also been identified, all sourced from
the pearl oyster Pinctada fucata. The three studies referenced above demonstrated the proteins’ ability
to enhance crystallisation of calcium carbonate in vitro. An ability to enhance differentiation of
osteoblast cell lines through various marker assays was also demonstrated, though the work of
Wang et al. [61] was the most comprehensive. Additionally, nacre appears to contain proteinase
inhibitors of varying molecular weights, which may help to conserve proteins important for processes
such as mineralisation [62]. The matrix hosts low molecular weight molecules, which were shown to
increase osteoblast mineralisation, Col-1 expression, and mRNA levels of Runx2 and osteopontin [63].
Overall then, these studies indicate that the effect of nacre, regardless of species, is due to the interaction
of a range of bioactive molecules present within the extract. However, the exact structure and action of
the majority remain to be identified.
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3. Algae and Seaweed
One group of marine invertebrates which show promise as a source of bioactives is algae,
particularly macroalgaes. Algae have a much greater bioactive diversity than nacre, including
calcareous extracts, sulphated polysaccharides, and raw algal extracts.
3.1. Aquamin
Aquamin is a food supplement derived from the red algae Lithothamnion corallioides, and contains
calcium, magnesium and 72 other trace minerals [30]. L. corallioides is fairly unique in that it is one
of the few algal species to produce a calcareous skeleton. It is normally found on muddy or sandy
substrates at less than 20 m in depth, in aggregations of unattached algae known as maerl beds [64].
It is from these beds, with a wide European (including western Irish and British shores) and more
northern distribution, that maerl is collected before it is ground into the commercial product known
as Aquamin. Currently, Aquamin is solely licenced to and produced by Marigot Limited (Marigot,
Cork, Ireland).
Mineralising organisms like L. corallioides are an obvious choice when searching for extracts to
promote bone health due to their structural similarities, and their tendency to contain similar key
molecules [65] and high mineral content. The latter is the theoretical basis of Aquamin, as there are
well established links between BMD and the intake of minerals such as calcium, magnesium, and
zinc [66]. From a cellular perspective, O’Gorman et al. [67] investigated the ability of Aquamin to
enhance mineralisation of a pre-osteoblastic cell line. Mineralisation did increase, though only at the
latest time point (Day 28), whilst other markers of osteoblast activity, for instance proliferation, did not
show significant differences between control and treatment. In vitro mineralisation is further enhanced
when vitamin D is included with Aquamin treatment, as compared to levels in osteoblast cultures
treated with only Aquamin or control solutions [68]. These studies appear to indicate that Aquamin
has some potential to increase mineralisation, though further work is needed.
Aquamin was tested in vivo by inclusion in the food of mice given a Western style diet, which
is known to detrimentally impact bone strength and mineralisation [69]. In this study, Aquamin
negated diet-related bone defects, supporting its potential to maintain healthy functioning of the BMU.
In another study, focusing on ovariectomized mice [70], Aquamin treatment increased mineral/matrix
ratio and the hydroxyapatite content of trabecular bone when compared to a calcium carbonate
treatment group. However, there was no significant difference in carbonate/phosphate ratio or
hydroxyapatite levels of cortical bone, whilst those positive effects observed were fairly small—casting
doubt on the eventual clinical potential of Aquamin. In vivo, the extract has also been shown to increase
bone turnover in horses, as supplementation studies have shown enhanced levels of osteocalcin and
type I collagen relative to limestone controls [71]. Interestingly, despite a lack of more basic studies,
two randomised control trials have been conducted, aimed at assessing the efficacy of Aquamin
supplementation in treating knee osteoarthritis [72,73]. These studies reported improvements in
outcome measures of mean walking distance and range of motion for Aquamin treatment compared
to controls. However, these results are limited due to the short study periods (12 weeks), lack of
long-term follow up, and small sample sizes used. Similarly, a pilot trial investigated the impact of
Aquamin F™ on markers of calcium metabolism, finding greater urinary clearance of calcium and a
suppression of PTH concentration [74]. However, this study only looked at changes in these markers
over a single 12 h period, meaning the long-term marker effects of Aquamin F™ treatment are yet to
be established. Overall, further in vitro and in vivo studies are required before the true potential of
Aquamin supplementation becomes apparent. Irrespective of its treatment prospects L. corallioides
is unlikely to be a long-term resource, as it has a slow growth rate (1–2 mm/year) and is highly
susceptible to sedimentation through natural or anthropogenic means [64].
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3.2. Fucoidan
Within the algal group, fucoidan is one of the best studied extracts. Fucoidans are highly sulphated
and fucose-rich polymers, found as a heavily branched and relatively high yield form in brown
macroalgae and a more linear form in echinoderms [75]. These marine polymers are multifunctional,
with a range of therapeutic uses, from anti-inflammatory to anti-viral [75].
In terms of its effects on bone tissue, it appears that the extract has both an anti-resorptive and
osteogenic potential. Fucoidan extracted from the sea cucumber Apostichopus japonicus has been shown
to inhibit osteoclastogenesis [43], whilst work by Kim et al. (2014) demonstrated the same effect
with brown algal extracts added to bone marrow macrophage cultures. This reduction in osteoclast
differentiation was attributed to inhibition of RANKL-dependent MAPKs and downregulation of c-Fos
and NFATc1 transcription factors. However, the precise molecular mechanism through which this
inhibition occurs is yet to be elucidated, which is a common limitation to studies on this polysaccharide.
It is speculated that fucoidan binds to either RANKL or RANK to inhibit intracellular signalling,
an action which may be facilitated by its sulphated regions [76].
With respect to osteogenic potential, low molecular weight fucoidan (LMWF) can promote
osteoblast proliferation in vitro. This was measured as increases in the presence of osteoblast markers
including ALP and type 1 collagen in 3D [77] and 2D culture [78]. The in vitro potential of fucoidan
was also demonstrated in work by Pereira et al. [79], whereby extract treatment increased osteogenic
differentiation as measured by ALP, osteopontin, Runx2, and calcium deposit formation in adipose
tissue-derived stem cells. Related work confirmed increased osteoblast differentiation of mesenchymal
stem cells upon fucoidan treatment, but also reported stimulation of angiogenic activities and
associated pathways. Furthermore, greater blood vessel formation, along with a small promotion of
bone formation, was also observed in a rabbit model of a calvarial bone defect [21]. Alternatively,
a related study showed that fucoidan extracts are also capable of impairing angiogenesis in co-culture
models relevant for bone vascularisation [80]. The two studies gave limited information on how each
fucoidan extract was prepared, though both used a different brown macroalgae source species and
fucoidan used by Wang et al. [80] is referred to as being ‘crude’. Differences in extract preparation may
therefore explain their differing effects on angiogenesis.
One limitation of current published studies testing fucoidan is a lack of in vivo experimentation,
which may simply be a function of the early developmental stage of much of this work. Of those few
in vivo studies conducted to date, fucoidan appears to have a positive effect on bone formation.
For example, LMWF was shown to increase femoral density and prevent microarchitectural
deterioration in ovariectomized Sprague-Dawley rats [22], whilst bone density and bone ash weight
of mice were also increased by LMWF treatment [81]. Further studies are required to fully detail the
in vivo potential of fucoidan, though this initial work is promising. Alternatively, fucoidan could be
applied to stimulate ex vivo osteogenic differentiation before in vivo re-implantation, though more
testing is required to confirm this.
To date, the most comprehensive study completed on fucoidan is that of Kim et al. [82], which
aimed to elucidate the complex mechanism by which the extract stimulates MSC differentiation into
osteoblasts. ALP, mRNA levels of multiple other markers, and alizarin red-S (AR-S) staining was
used to determine osteoblast differentiation and mineralisation, whilst Western blotting was also
conducted, including antibodies for various intracellular signalling pathway proteins. The results
indicated that BMP2-Smad 1/5/8 signalling was responsible for stimulating osteoblast differentiation
through activation of ERK and JNK pathways.
3.3. Other Algal Bioactives
Whilst fucoidan is one of the better known bioactives, there are other marine algae extracts that
also have an effect on bone homeostasis. Extracts from the brown algae Sargassum horneri are known to
stimulate osteoblastogenesis and inhibit osteoclastogenesis in vitro in preosteoblastic and monocytic
cell lines [24]. Similar in vitro and in vivo work was conducted using rat femoral tissues, which
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demonstrated the ability of S. horneri extracts to increase their bone calcium content [83] and inhibit
bone resorption [84]. Such work complements in vivo tests, which indicate that S. horneri extracts
have a preventative effect on bone loss in streptozotocin-diabetic rats [85]. Furthermore, there has
even been a basic human trial investigating the effect of oral intake of the algae on bone metabolic
markers [86]. Despite being limited by very small sample sizes, this study reported an inhibitory
effect of the extract on bone resorption, as determined by decreased levels of circulating resorption
markers such as TRAP, and is one of the few human trial studies conducted for any marine based
compound. As with fucoidan, the main limitation to the S. horneri body of work lies in identifying the
active component of the extract, which appears to be different for bone stimulation and suppression of
resorption [83].
Another brown algae extract which has been tested both in vitro and in vivo is Hizikia
fusiforme [27]. Specifically, a hot water by-product of the algae which contained high polysaccharide
levels was shown to stimulate ALP activity and BMP-2 levels in mouse myoblast C2C12 cells.
Furthermore, in vivo stimulations of skeletal activity were confirmed in zebrafish, ovariectomized mice,
and mouse calvaria bones [27]. Similarly, a brown alga-based study investigated quinone derivatives
from Sargassum thunbergii, finding that treatment with a crude extract containing these derivatives
was able to enhance osteoblast differentiation [26]. Finally, fucoxanthin—a marine carotenoid present
in brown seaweeds—has also been tested for osteogenic activity. Fucoxanthin administered to rats
was shown to significantly decrease the oxidative stress index [23], but had no significant effect on
ALP levels and only caused a limited reduction in alveolar bone resorption—despite significantly
reducing RANKL levels. Similarly, a related study found that fucoxanthin had no effect on MC3T3-E1
(an osteoblast cell line) viability, but did stimulate apoptosis in osteoclasts [87]. As yet, research on this
carotenoid is limited and so it is difficult to determine its in vitro effects, though it initially appears to
inhibit osteoclast resorption rather than stimulating osteoblast activity.
In addition to Phaeophycae, green and red algae also contain examples of extracts which are
able to stimulate osteogenic activity. Extracts from two marine green macroalgae, Cladophora rupestris
and Codium fragile, were shown to increase osteogenic activity. These extracts were enriched in
phenolic compounds and able to stimulate mineralogenic activity of a fish bone-derived cell line,
as well as 1.5 fold increases in the operculum area of juvenile zebrafish [28]. Similarly, extracts
from two red algae—Plocamium cartilagineum and Ceramium secundatum—increased activity of human
bone marrow stromal cells (hBMSCs) and caused significant increases in the size of opercular bones
in juvenile zebrafish [88]. Another red alga-derived osteogenic bioactive is floridoside, a glycerol
glycoside metabolite of Laurencia undulata (amongst other red algae). Floridoside is known to promote
differentiation of osteoblast D1 cells, as well as increasing ALP levels, mineralisation and expression of
factors including type I collagen, Runx-2, and Osterix [29].
The studies discussed appear to indicate that algae may be a promising reserve of bioactive
compounds, whilst the ease of sourcing these inshore and shallow water eukaryotes makes them a
likely commercial source. However, it is apparent that more in vivo studies are needed, as well
as a focus on the mechanisms involved and the active molecular component of algal extracts.
One potential solution is the use of in vivo zebrafish models, as employed in two of the aforementioned
studies [28,88], as these allow for inexpensive and rapid determination of osteogenic potential and the
mechanisms/pathways involved in activity [89].
4. Assorted Taxa
There are numerous examples of taxa and extracts that have only undergone initial screening,
many of which show osteogenic potential. The aforementioned abalone gastro-intestinal digests
from Haliotis discus hannai promote osteoblast activity, but to date have only been reported in a
single study [44]. Norzoanthamine (see Figure 2 for chemical structure), an alkaloid isolated from
a colonial zoanthid, Zoanthus sp., is also known to have anabolic effects on bone, accelerating
the formation of a collagen-hydroxyapatite composite [38]. It is particularly effective at binding
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collagen and has been previously shown to suppress decreases in various parameters indicative
of bone health in ovariectomized mice [90]. Another natural marine compound with osteogenic
potential is Phorbaketal A, derived from the marine sponge Phorbas sp. This bioactive was shown to
stimulate osteoblast differentiation in mesenchymal stem cells, predominantly through activation of
the extracellular signal-regulated kinase (ERK) pathway [37]. Mussel adhesive proteins are also of
interest as they are known to increase cell proliferation and osteogenic differentiation, and can be used
to easily coat graft materials [46]. This, along with their biocompatibility and biodegradability, makes
them promising adjuncts to synthetic grafts. These preliminary studies (and those of Sections 4.1
and 4.2), looking at various markers of cell-stimulation potential, highlight the diversity of marine
bioactives and indicate that it is primarily research effort which determines success within this field.
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4.1. Microalgae
There are a number of bioactives that have been isolated from microalgae that show osteogenic
potential. The polyketide amphirionin-4 was isolated from Amphidinium sp.—a marine dinoflagellate.
Application of only 0.1 ng/mL amphirionin-4 stimulated a 950% promotion in murine bone marrow
stromal ST-2 cell proliferation [33]. Similar proliferative effects were also observed from experiments
using amphirionin-5, with a 282% proliferation increase in murine bone-marrow derived stromal ST-2
cells and a 320% increase for MC3T3-E1 cells [91]. Another marine dinoflagellate derived compound is
symbioimine, from Symbiodinium sp. This secondary metabolite is anti-resorptive in nature, inhibiting
the differentiation of RAW264 cells into osteoclasts [32]. Biselyngbyaside, a macrolide compound
from marine cyanobacteria Lyngbya sp., also inhibits osteoclastogenesis and induces apoptosis in
mature osteoclasts [31]. Similar results are presented for a range of extracts, such as microalgae
byproducts [34] and a depsipeptide (largazole) sourced from cyanobacteria [92]. Another interesting
prokaryote is Alteromonas infernus, which is a deep sea species known to produce a high molecular
weight polysaccharide. This oversulphated polysaccharide increased chondrogenesis in vitro, via the
MAPK pathway, and may consequently be a potential therapy for cartilage repair [35].
4.2. Corals
Corals, of the phylum Cnidaria and class Anthozoa, are another group which have received
surprisingly little attention. This phylum includes mineralising species, which have a skeleton
comprised of calcium carbonate either in the form of calcite, aragonite or a mixture of the two,
as with the Scleractinian or stony corals [93]. Like those taxa containing nacre, coral skeletons also
include an organic phase, comprised of proteins, polysaccharides, lipids, and glycosaminoglycans [65].
Marine invertebrates such as corals have a long evolutionary history of developing proteins and
genes that govern biomineralisation, many of which are highly conserved and analogous to human
variants [65]. In scleractinians, both soluble and insoluble components of the organic matrix can
influence calcium carbonate precipitation [94]. More specifically, multiple species express BMP2/4
orthologs, which show specificity to murine BMP receptors despite the taxonomical distance between
the two groups [95]. This indicates incredible conservation of the protein sequence over time and
suggests other proteins of skeletal importance may also be present within coral tissue. The presence of
these bioactives is also supported by the regenerative ability of corals, many of which show relatively
rapid skeletal repair, particularly those species living in shallow water, high-energy environments [96].
Despite their significance as a potential source of bioactive molecules, research using coral extracts is
limited. Instead, the majority of research has focused on their potential as a scaffold material for graft
procedures, due to their structural and compositional similarities to human bone [14].
5. Challenges to Using Marine Bioactives
Conservation concerns are an important consideration when looking for potential bioactive
sources. Taking corals as an example, it is well known that the world’s populations are a serious
conservation issue [97], with both cold and warm water species showing declining abundance
and many listed in the Convention on International Trade in Endangered Species (CITES) list [98].
Reasons for the decline are varied, including increasing water temperature and ocean acidification
associated with climate change, as well as damage from trawling, dynamite fishing, aquarium stocking,
and various forms of anthropogenic pollution [97]. This, coupled with slow growth rates, a long time
to maturity, and relatively limited ecological niches, means further declines in coral numbers are likely.
The sustainability of these invertebrates as a source of bioactives is therefore questionable, although
some species such as Millepora dichotoma are more abundant and show promise for aquaculture
production [39]. Though corals are perhaps an extreme example in terms of sustainability, many
marine invertebrates suffer from low abundance or long development cycles. In these cases bacterial
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cultures (modified to express the bioactive) or synthetic production are potential solutions, though
complex molecule structures often make this challenging [99].
Aquaculture may become a necessity if commercial bioactives are to be sourced from marine
organisms, as yields of target compounds are often very low, needing a large quantity of raw
material for significant extraction [99]. In particular, secondary metabolite yields tend to be very
low, though structural and non-metabolic proteins (like many of those with skeletal importance) tend
to have higher yields [65]. Even if yield is not an issue, aquaculture comes with a whole host of
other challenges involved in maintaining a large-scale culture system. Algal aquaculture requires
consideration of temperature, light levels, hydrodynamic and general stress levels, as well as many
other factors [100]. These, coupled with harvesting and processing complexities, mean that aquaculture
systems are often inefficient and not cost-effective. Another concern is the spread of invasive species,
as aquaculture is thought to be a major source of introduction for invaders—such as the brown alga
Undaria pinnatifida [101]. Finally, it is also necessary to consider the costs and difficulties associated
with collecting enough quality specimens in the first place, an issue which is further complicated
when sourcing deep sea species. Advances in technology, such as the development of sophisticated
remotely operated vehicles (ROVs), is beginning to make collection of these specimens more feasible.
However, production and use of ROVs is expensive and often involves long voyages and use of a large
vessel—further raising costs. In shallow water areas (<50 m depth), SCUBA diving is still the most
effective method of sample collection. However, despite being more affordable, diving for samples is
time-consuming, particularly compared to terrestrial sampling methods.
6. Conclusions
Osteoporosis is particularly prevalent in aged populations, a fact which is daunting considering
estimations that by 2030 20% of Europeans and 30% of the US population will be over the age of
65 [102]. It is therefore in the best interests of patients, governments and health services to develop
effective treatment options now. Furthermore, should an effective osteogenic bioactive be found,
there are many more clinical applications for such a therapy. This review has demonstrated that
marine organisms, such as molluscs and algae, are a highly promising source of osteogenic compounds.
Algal sources in particular show excellent potential, as there are already indications of activity with
limited study effort. This, coupled with other factors like ease of sampling, their great diversity, large
secondary metabolite production, and quick growth times, make them excellent candidates as target
source organisms.
Despite the possibility for drug discovery within this field, current research is highly limited.
Compared to the huge diversity of marine organisms, only a fraction have been tested for their
bioactivity, and even fewer specifically for osteogenic activity. More research is required across all
taxonomic groups. At present, in vitro descriptions of activity are generally well detailed, though many
studies lack identification of the bioactive structure and mechanism of activity. Furthermore, in vivo
work is limited and needs greater focus in future studies, whilst human trials are even rarer—though
arguably this is a reflection of the current phase of much research within the field.
In conclusion, marine bioactives are a highly promising reserve of osteogenic compounds, as well
as bioactives in general. The dearth of research in this area increases discovery potential, making it an
exciting field to conduct research in. Greater study effort would likely lead to the discovery of effective
treatment options for osteoporosis and other conditions, reducing health care burden and improving
patient quality of life.
Author Contributions: M.A.C. wrote the manuscript. S.A.C. edited the manuscript and helped review
the literature.
Funding: This research received no external funding.
Conflicts of Interest: The authors declare no conflict of interest.
Mar. Drugs 2018, 16, 340 11 of 16
References
1. Johnell, O.; Kanis, J.A. An estimate of the worldwide prevalence and disability associated with osteoporotic
fractures. Osteoporos. Int. 2006, 17, 1726–1733. [CrossRef] [PubMed]
2. Kanis, J.A. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis:
Synopsis of a WHO report. Osteoporos. Int. 1994, 4, 368–381. [CrossRef] [PubMed]
3. Kanis, J.A.; Johnell, O.; Oden, A.; Johansson, H.; McCloskey, E. FRAXTM and the assessment of fracture
probability in men and women from the UK. Osteoporos. Int. 2008, 19, 385–397. [CrossRef] [PubMed]
4. Riggs, B.L.; Khosla, S.; Melton, L.J. A unitary model for involutional osteoporosis: Estrogen deficiency causes
both type I and type II osteoporosis in postmenopausal women and contributes to bone loss in aging men.
J. Bone Miner. Res. 1998, 13, 763–773. [CrossRef] [PubMed]
5. Lips, P.; Bouillon, R.; Van Schoor, N.M.; Vanderschueren, D.; Verschueren, S.; Kuchuk, N.; Milisen, K.;
Boonen, S. Reducing fracture risk with calcium and vitamin D. Clin. Endocrinol. 2010, 73, 277–285. [CrossRef]
[PubMed]
6. Hernlund, E.; Svedbom, A.; Ivergård, M.; Compston, J.; Cooper, C.; Stenmark, J.; McCloskey, E.V.; Jönsson, B.;
Kanis, J.A. Osteoporosis in the European Union: Medical management, epidemiology and economic burden:
A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European
Federation of Pharmaceutical Industry Associations (EFPIA). Arch. Osteoporos. 2013, 8. [CrossRef] [PubMed]
7. Adler, R.A.; El-Hajj Fuleihan, G.; Bauer, D.C.; Camacho, P.M.; Clarke, B.L.; Clines, G.A.; Compston, J.E.;
Drake, M.T.; Edwards, B.J.; Favus, M.J.; et al. Managing Osteoporosis in Patients on Long-Term
Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research.
J. Bone Miner. Res. 2016, 31, 16–35. [CrossRef] [PubMed]
8. Bilezikian, J.P. Efficacy of Bisphosphonates in Reducing Fracture Risk in Postmenopausal Osteoporosis.
Am. J. Med. 2009, 122, S14–S21. [CrossRef] [PubMed]
9. Ensrud, K.E.; Barrett-Connor, E.L.; Schwartz, A.; Santora, A.C.; Bauer, D.C.; Suryawanshi, S.; Feldstein, A.;
Haskell, W.L.; Hochberg, M.C.; Torner, J.C.; et al. Randomized Trial of Effect of Alendronate Continuation
Versus Discontinuation in Women With Low BMD: Results From the Fracture Intervention Trial Long-Term
Extension. J. Bone Miner. Res. 2004, 19, 1259–1269. [CrossRef] [PubMed]
10. Black, D.M.; Rosen, C.J. Postmenopausal Osteoporosis. N. Engl. J. Med. 2016, 374, 254–262. [CrossRef]
[PubMed]
11. Canalis, E.; Giustina, A.; Bilezikian, J.P. Mechanisms of anabolic therapies for osteoporosis. N. Engl. J. Med.
2007, 357, 905–916. [CrossRef] [PubMed]
12. Charissoux, J.-L.; Vergnenegre, G.; Pelissier, M.; Fabre, T.; Mansat, P. Epidemiology of distal humerus
fractures in the elderly. Orthop. Traumatol. Surg. Res. 2013, 99, 765–769. [CrossRef] [PubMed]
13. Ringe, J.; Kaps, C.; Burmester, G.-R.; Sittinger, M. Stem cells for regenerative medicine: Advances in the
engineering of tissues and organs. Naturwissenschaften 2002, 89, 338–351. [CrossRef] [PubMed]
14. Clarke, S.A.; Walsh, P.; Maggs, C.A.; Buchanan, F. Designs from the deep: Marine organisms for bone tissue
engineering. Biotechnol. Adv. 2011, 29, 610–617. [CrossRef] [PubMed]
15. Granito, R.N.; Custódio, M.R.; Rennó, A.C.M. Natural marine sponges for bone tissue engineering: The state
of art and future perspectives. J. Biomed. Mater. Res. Part B Appl. Biomater. 2017, 105, 1717–1727. [CrossRef]
[PubMed]
16. Lordan, S.; Ross, R.P.; Stanton, C. Marine bioactives as functional food ingredients: Potential to reduce the
incidence of chronic diseases. Mar. Drugs 2011, 9, 1056–1100. [CrossRef] [PubMed]
17. Smith, V.J.; Desbois, A.P.; Dyrynda, E.A. Conventional and Unconventional Antimicrobials from Fish, Marine
Invertebrates and Micro-algae. Mar. Drugs 2010, 8, 1213–1262. [CrossRef] [PubMed]
18. Rasmussen, R.S.; Morrissey, M.T. Marine Biotechnology for Production of Food Ingredients. Adv. Food Nutr. Res.
2007, 52, 237–292. [CrossRef] [PubMed]
19. Jha, R.K.; Zi-rong, X. Biomedical Compounds from Marine organisms. Mar. Drugs 2004, 2, 123–146.
[CrossRef]
20. Senthilkumar, K.; Venkatesan, J.; Kim, S.-K. Marine derived natural products for osteoporosis. Biomed. Prev. Nutr.
2014, 4, 1–7. [CrossRef]
Mar. Drugs 2018, 16, 340 12 of 16
21. Kim, B.-S.; Yang, S.-S.; You, H.-K.; Shin, H.-I.; Lee, J. Fucoidan-induced osteogenic differentiation promotes
angiogenesis by inducing vascular endothelial growth factor secretion and accelerates bone repair. J. Tissue
Eng. Regen. Med. 2018, 12, e1311–e1324. [CrossRef] [PubMed]
22. Jin, X.; Zhu, L.; Li, X.; Jia, J.; Zhang, Y.; Sun, X.; Ma, J.; Liu, Z.; Ma, X. Low-molecular weight fucoidan inhibits
the differentiation of osteoclasts and reduces osteoporosis in ovariectomized rats. Mol. Med. Rep. 2017, 15,
890–898. [CrossRef] [PubMed]
23. Kose, O.; Arabaci, T.; Yemenoglu, H.; Kara, A.; Ozkanlar, S.; Kayis, S.; Duymus, Z. Influences of Fucoxanthin
on Alveolar Bone Resorption in Induced Periodontitis in Rat Molars. Mar. Drugs 2016, 14, 70. [CrossRef]
[PubMed]
24. Yamaguchi, M.; Matsumoto, T. Marine Algae Sargassum Horneri Bioactive Factor Stimulates Osteoblastogenesis
and Suppresses Osteoclastogenesis in Vitro. OA Biotechnol. 2012, 1, 3. [CrossRef]
25. Yoon, W.-J.; Kim, K.-N.; Heo, S.-J.; Han, S.-C.; Kim, J.; Ko, Y.-J.; Kang, H.-K.; Yoo, E.-S. Sargachromanol G
inhibits osteoclastogenesis by suppressing the activation NF-κB and MAPKs in RANKL-induced RAW 264.7
cells. Biochem. Biophys. Res. Commun. 2013, 434, 892–897. [CrossRef] [PubMed]
26. Kim, J.-A.; Karadeniz, F.; Ahn, B.-N.; Kwon, M.S.; Mun, O.-J.; Bae, M.J.; Seo, Y.; Kim, M.; Lee, S.-H.; Kim, Y.Y.;
et al. Bioactive quinone derivatives from the marine brown alga Sargassum thunbergii induce anti-adipogenic
and pro-osteoblastogenic activities. J. Sci. Food Agric. 2016, 96, 783–790. [CrossRef] [PubMed]
27. Jeong, Y.T.; Baek, S.H.; Jeong, S.C.; Yoon, Y.D.; Kim, O.H.; Oh, B.C.; Jung, J.W.; Kim, J.H. Osteoprotective
Effects of Polysaccharide-Enriched Hizikia fusiforme Processing Byproduct In Vitro and In Vivo Models.
J. Med. Food 2016, 19, 805–814. [CrossRef] [PubMed]
28. Surget, G.; Roberto, V.P.; Le Lann, K.; Mira, S.; Guérard, F.; Laizé, V.; Poupart, N.; Cancela, M.L.;
Stiger-Pouvreau, V. Marine green macroalgae: A source of natural compounds with mineralogenic and
antioxidant activities. J. Appl. Phycol. 2017, 29, 575–584. [CrossRef]
29. Ryu, B.; Li, Y.-X.; Kang, K.-H.; Kim, S.-K.; Kim, D.G. Floridoside from Laurencia undulata promotes osteogenic
differentiation in murine bone marrow mesenchymal cells. J. Funct. Foods 2015, 19, 505–511. [CrossRef]
30. Gorman, D.M.O.; Carroll, C.O.; Carmody, R.J. Evidence that Marine-derived, Multi-mineral, Aquamin
Inhibits the NF-k B Signaling Pathway in Vitro. Phyther. Res. 2011, 4, 630–632.
31. Yonezawa, T.; Mase, N.; Sasaki, H.; Teruya, T.; Hasegawa, S.; Cha, B.-Y.; Yagasaki, K.; Suenaga, K.; Nagai, K.;
Woo, J.-T. Biselyngbyaside, isolated from marine cyanobacteria, inhibits osteoclastogenesis and induces
apoptosis in mature osteoclasts. J. Cell. Biochem. 2012, 113, 440–448. [CrossRef] [PubMed]
32. Kita, M.; Kondo, M.; Koyama, T.; Yamada, K.; Matsumoto, T.; Lee, K.H.; Woo, J.T.; Uemura, D. Symbioimine
Exhibiting Inhibitory Effect of Osteoclast Differentiation, from the Symbiotic Marine Dinoflagellate
Symbiodinium sp. J. Am. Chem. Soc. 2004, 126, 4794–4795. [CrossRef] [PubMed]
33. Minamida, M.; Kumagai, K.; Ulanova, D.; Akakabe, M.; Konishi, Y.; Tominaga, A.; Tanaka, H.; Tsuda, M.;
Fukushi, E.; Kawabata, J.; et al. Amphirionin-4 with Potent Proliferation-Promoting Activity on Bone Marrow
Stromal Cells from a Marine Dinoflagellate Amphidinium Species. Org. Lett. 2014, 16, 4858–4861. [CrossRef]
[PubMed]
34. Nguyen, M.H.T.; Qian, Z.-J.; Nguyen, V.-T.; Choi, I.-W.; Heo, S.-J.; Oh, C.H.; Kang, D.-H.; Kim, G.H.;
Jung, W.-K. Tetrameric peptide purified from hydrolysates of biodiesel byproducts of Nannochloropsis
oculata induces osteoblastic differentiation through MAPK and Smad pathway on MG-63 and D1 cells.
Process Biochem. 2013, 48, 1387–1394. [CrossRef]
35. Merceron, C.; Portron, S.; Vignes-Colombeix, C.; Rederstorff, E.; Masson, M.; Lesoeur, J.; Sourice, S.;
Sinquin, C.; Colliec-Jouault, S.; Weiss, P.; et al. Pharmacological modulation of human mesenchymal
stem cell chondrogenesis by a chemically oversulfated polysaccharide of marine origin: Potential application
to cartilage regenerative medicine. Stem Cells 2012, 30, 471–480. [CrossRef] [PubMed]
36. Lee, S.; Kwak, H.B.; Pi, S.; You, H.; Byeon, S.R.; Ying, Y.; Luesch, H.; Hong, J.; Kim, S.H. In Vitro and In Vivo
Osteogenic Activity of Largazole. Am. Chem. Soc. Med. Chem. Lett. 2011, 2, 248–251. [CrossRef] [PubMed]
37. Byun, M.R.; Kim, A.R.; Hwang, J.-H.; Sung, M.K.; Lee, Y.K.; Hwang, B.S.; Rho, J.-R.; Hwang, E.S.; Hong, J.-H.
Phorbaketal A stimulates osteoblast differentiation through TAZ mediated Runx2 activation. FEBS Lett.
2012, 586, 1086–1092. [CrossRef] [PubMed]
38. Kinugawa, M.; Fukuzawa, S.; Tachibana, K. Skeletal protein protection: The mode of action of an
anti-osteoporotic marine alkaloid, norzoanthamine. J. Bone Miner. Metab. 2009, 27, 303–314. [CrossRef]
[PubMed]
Mar. Drugs 2018, 16, 340 13 of 16
39. Abramovitch-gottlib, L.; Sc, M.; Geresh, S.; Vago, R.; Ph, D. Biofabricated Marine Hydrozoan: A Bioactive
Crystalline Material Promoting Ossification of Mesenchymal Stem Cells. Tissue Eng. 2006, 12, 729–739.
[CrossRef] [PubMed]
40. DiCarlo, B.B.; Hu, J.C.; Gross, T.; Vago, R.; Athanasiou, K.A. Biomaterial effects in articular cartilage tissue
engineering using polyglycolic acid, a novel marine origin biomaterial, IGF-I, and TGF-β1. Proc. Inst. Mech.
Eng. Part H J. Eng. Med. 2009, 223, 63–73. [CrossRef] [PubMed]
41. Rahman, M.A.; Isa, Y.; Uehara, T. Proteins of calcified endoskeleton: II partial amino acid sequences
of endoskeletal proteins and the characterization of proteinaceous organic matrix of spicules from the
alcyonarian, Synularia polydactyla. Proteomics 2005, 5, 885–893. [CrossRef] [PubMed]
42. Helman, Y.; Natale, F.; Sherrell, R.M.; Lavigne, M.; Starovoytov, V.; Gorbunov, M.Y.; Falkowski, P.G.
Extracellular matrix production and calcium carbonate precipitation by coral cells in vitro. Proc. Natl.
Acad. Sci. USA 2008, 105, 54–58. [CrossRef] [PubMed]
43. Kariya, Y.; Mulloy, B.; Imai, K.; Tominaga, A.; Kaneko, T.; Asari, A.; Suzuki, K.; Masuda, H.; Kyogashima, M.;
Ishii, T. Isolation and partial characterization of fucan sulfates from the body wall of sea cucumber Stichopus
japonicus and their ability to inhibit osteoclastogenesis. Carbohydr. Res. 2004, 339, 1339–1346. [CrossRef]
[PubMed]
44. Nguyen, M.H.T.; Qian, Z.-J.; Jung, W.-K. Beneficial Effect of Abalone Intestine Gastro-Intestinal Digests on
Osteoblastic MG-63 Cell Differentiation. J. Aquat. Food Prod. Technol. 2014, 23, 436–446. [CrossRef]
45. Weiss, I.M.; Göhring, W.; Fritz, M.; Mann, K. Perlustrin, a Haliotis laevigata (abalone) nacre protein,
is homologous to the insulin-like growth factor binding protein N-terminal module of vertebrates.
Biochem. Biophys. Res. Commun. 2001, 285, 244–249. [CrossRef] [PubMed]
46. Hong, J.M.; Kim, B.J.; Shim, J.-H.; Kang, K.S.; Kim, K.-J.; Rhie, J.W.; Cha, H.J.; Cho, D.-W. Enhancement of bone
regeneration through facile surface functionalization of solid freeform fabrication-based three-dimensional
scaffolds using mussel adhesive proteins. Acta Biomater. 2012, 8, 2578–2586. [CrossRef] [PubMed]
47. Oliveira, D.V.; Silva, T.S.; Cordeiro, O.D.; Cavaco, S.I.; Simes, D.C. Identification of proteins with potential
osteogenic activity present in the water-soluble matrix proteins from Crassostrea gigas nacre using a proteomic
approach. Sci. World J. 2012, 2012, 765909. [CrossRef] [PubMed]
48. Almeida, M.J.; Milet, C.; Peduzzi, J.; Pereira, L.; Haigle, J.; Barthelemy, M.; Lopez, E. Effect of water-soluble
matrix fraction extracted from the nacre of Pinctada maxima on the alkaline phosphatase activity of cultured
fibroblasts. J. Exp. Zool. 2000, 288, 327–334. [CrossRef]
49. Kim, H.; Lee, K.; Ko, C.-Y.; Kim, H.-S.; Shin, H.-I.; Kim, T.; Lee, S.H.; Jeong, D. The role of nacreous factors in
preventing osteoporotic bone loss through both osteoblast activation and osteoclast inactivation. Biomaterials
2012, 33, 7489–7496. [CrossRef] [PubMed]
50. Bédouet, L.; Marie, A.; Dubost, L.; Péduzzi, J.; Duplat, D.; Berland, S.; Puisségur, M.; Boulzaguet, H.;
Rousseau, M.; Milet, C.; et al. Proteomics analysis of the nacre soluble and insoluble proteins from the oyster
Pinctada margaritifera. Mar. Biotechnol. 2007, 9, 638–649. [CrossRef] [PubMed]
51. Lao, Y.; Zhang, X.; Zhou, J.; Su, W.; Chen, R.; Wang, Y.; Zhou, W.; Xu, Z.-F. Characterization and in vitro
mineralization function of a soluble protein complex P60 from the nacre of Pinctada fucata. Comp. Biochem.
Physiol. B Biochem. Mol. Biol. 2007, 148, 201–208. [CrossRef] [PubMed]
52. Benkendorff, K. Molluscan biological and chemical diversity: Secondary metabolites and medicinal resources
produced by marine molluscs. Biol. Rev. 2010, 85. [CrossRef] [PubMed]
53. Grienke, U.; Silke, J.; Tasdemir, D. Bioactive compounds from marine mussels and their effects on human
health. Food Chem. 2014, 142, 48–60. [CrossRef] [PubMed]
54. Marie, B.; Marin, F.; Marie, A.; Bédouet, L.; Dubost, L.; Alcaraz, G.; Milet, C.; Luquet, G. Evolution of
nacre: Biochemistry and proteomics of the shell organic matrix of the cephalopod Nautilus macromphalus.
Chembiochem 2009, 10, 1495–1506. [CrossRef] [PubMed]
55. Silve, C.; Lopez, E.; Vidal, B.; Smith, D.C.; Camprasse, S.; Camprasse, G.; Couly, G. Nacre Initiâtes
Biomineralization by Human Osteoblasts Maintained in Vitro. Calcif. Tissue Int. 1992, 51, 363–369. [CrossRef]
[PubMed]
56. Atlan, G.; Balmain, N.; Berland, S.; Vidal, B.; Lopez, E. Reconstruction of human maxillary defects with nacre
powder: Histological evidence for bone regeneration. C. R. Acad. Sci. III 1997, 320, 253–258. [CrossRef]
57. Westbroek, P.; Marin, F. A marriage of bone and nacre. Nature 1998, 392, 861–862. [CrossRef] [PubMed]
Mar. Drugs 2018, 16, 340 14 of 16
58. Chaturvedi, R.; Singha, P.K.; Dey, S. Water soluble bioactives of nacre mediate antioxidant activity and
osteoblast differentiation. PLoS ONE 2013, 8, e84584. [CrossRef] [PubMed]
59. Liao, H.; Mutvei, H.; Hammarström, L.; Wurtz, T.; Li, J. Tissue responses to nacreous implants in rat femur:
An in situ hybridization and histochemical study. Biomaterials 2002, 23, 2693–2701. [CrossRef]
60. Zhang, C.; Li, S.; Ma, Z.; Xie, L.; Zhang, R. A novel matrix protein p10 from the nacre of pearl oyster
(Pinctada fucata) and its effects on both CaCO3 crystal formation and mineralogenic cells. Mar. Biotechnol.
2006, 8, 624–633. [CrossRef] [PubMed]
61. Wang, X.; Liu, S.; Xie, L.; Zhang, R.; Wang, Z. Pinctada fucata mantle gene 3 (PFMG3) promotes differentiation
in mouse osteoblasts (MC3T3-E1). Comp. Biochem. Physiol. B Biochem. Mol. Biol. 2011, 158, 173–180.
[CrossRef] [PubMed]
62. Bédouet, L.; Duplat, D.; Marie, A.; Dubost, L.; Berland, S.; Rousseau, M.; Milet, C.; Lopez, E. Heterogeneity
of proteinase inhibitors in the water-soluble organic matrix from the oyster nacre. Mar. Biotechnol. 2007, 9,
437–449. [CrossRef] [PubMed]
63. Rousseau, M.; Boulzaguet, H.; Biagianti, J.; Duplat, D.; Milet, C.; Lopez, E.; Bédouet, L. Low molecular
weight molecules of oyster nacre induce mineralization of the MC3T3-E1 cells. J. Biomed. Mater. Res. A 2008,
85, 487–497. [CrossRef] [PubMed]
64. Wilson, S.; Blake, C.; Berges, J.A.; Maggs, C.A. Environmental tolerances of free-living coralline algae (maerl):
Implications for European marine conservation. Biol. Conserv. 2004, 120, 279–289. [CrossRef]
65. Green, D.W.; Padula, M.P.; Santos, J.; Chou, J.; Milthorpe, B.; Ben-Nissan, B. A therapeutic potential for
marine skeletal proteins in bone regeneration. Mar. Drugs 2013, 11, 1203–1220. [CrossRef] [PubMed]
66. Palacios, C. The role of nutrients in bone health, from A to Z. Crit. Rev. Food Sci. Nutr. 2006, 46, 621–628.
[CrossRef] [PubMed]
67. Gorman, D.M.O.; Tierney, C.M.; Brennan, O.; Brien, F.J.O. The Marine-derived, Multi-mineral formula,
Aquamin, Enhances Mineralisation of Osteoblast Cells In Vitro. Phyther. Res. 2012, 380, 375–380.
68. Widaa, A.; Brennan, O.; Gorman, D.M.O.; Brien, F.J.O. The Osteogenic Potential of the Marine-Derived
Multi-Mineral Formula Aquamin Is Enhanced by the Presence of Vitamin D. Phyther. Res. 2014, 684, 678–684.
[CrossRef] [PubMed]
69. Aslam, M.N.; Kreider, J.M.; Paruchuri, T.; Bhagavathula, N.; DaSilva, M.; Zernicke, R.F.; Goldstein, S.A.;
Varani, J. A mineral-rich extract from the red marine algae Lithothamnion calcareum preserves bone structure
and function in female mice on a Western-style diet. Calcif. Tissue Int. 2010, 86, 313–324. [CrossRef] [PubMed]
70. Brennan, O.; Stenson, B.; Widaa, A.; O’Gorman, D.M.; O’Brien, F.J. Incorporation of the natural marine
multi-mineral dietary supplement Aquamin enhances osteogenesis and improves the mechanical properties
of a collagen-based bone graft substitute. J. Mech. Behav. Biomed. Mater. 2015, 47, 114–123. [CrossRef]
[PubMed]
71. Nielsen, B.D.; Cate, R.E.; O’Connor-Robison, C.I. A Marine Mineral Supplement Alters Markers of Bone
Metabolism in Yearling Arabians. J. Equine Vet. Sci. 2010, 30, 419–424. [CrossRef]
72. Frestedt, J.L.; Kuskowski, M.A.; Zenk, J.L. A natural seaweed derived mineral supplement (Aquamin F) for
knee osteoarthritis: A randomised, placebo controlled pilot study. Nutr. J. 2009, 8, 7. [CrossRef] [PubMed]
73. Frestedt, J.L.; Walsh, M.; Kuskowski, M.A.; Zenk, J.L. A natural mineral supplement provides relief from
knee osteoarthritis symptoms: A randomized controlled pilot trial. Nutr. J. 2008, 7, 9. [CrossRef] [PubMed]
74. Zenk, J.L.; Frestedt, J.L.; Kuskowski, M.A. Effect of Calcium Derived from Lithothamnion sp. on Markers of
Calcium Metabolism in Premenopausal Women. J. Med. Food 2018, 21, 154–158. [CrossRef] [PubMed]
75. Fitton, J.H. Therapies from fucoidan; multifunctional marine polymers. Mar. Drugs 2011, 9, 1731–1760.
[CrossRef] [PubMed]
76. Kim, Y.W.; Baek, S.-H.; Lee, S.-H.; Kim, T.-H.; Kim, S.-Y. Fucoidan, a Sulfated Polysaccharide, Inhibits
Osteoclast Differentiation and Function by Modulating RANKL Signaling. Int. J. Mol. Sci. 2014, 15,
18840–18855. [CrossRef] [PubMed]
77. Changotade, S.I.T.; Korb, G.; Bassil, J.; Barroukh, B.; Willig, C.; Colliec-Jouault, S.; Durand, P.; Godeau, G.;
Senni, K. Potential effects of a low-molecular-weight fucoidan extracted from brown algae on bone
biomaterial osteoconductive properties. J. Biomed. Mater. Res. Part A 2008, 87, 666–675. [CrossRef]
[PubMed]
Mar. Drugs 2018, 16, 340 15 of 16
78. Cho, Y.-D.; Yoon, W.-J.; Woo, K.-M.; Baek, J.-H.; Lee, G.; Cho, J.-Y.; Ryoo, H.-M. Molecular regulation of
matrix extracellular phosphoglycoprotein expression by bone morphogenetic protein-2. J. Biol. Chem. 2009,
284, 25230–25240. [CrossRef] [PubMed]
79. Pereira, J.; Portron, S.; Dizier, B.; Vinatier, C.; Masson, M.; Sourice, S.; Galy-Fauroux, I.; Corre, P.; Weiss, P.;
Fischer, A.-M.; et al. The in vitro and in vivo effects of a low-molecular-weight fucoidan on the osteogenic
capacity of human adipose-derived stromal cells. Tissue Eng. Part A 2014, 20, 275–284. [CrossRef] [PubMed]
80. Wang, F.; Schmidt, H.; Pavleska, D.; Wermann, T.; Seekamp, A.; Fuchs, S. Crude Fucoidan Extracts Impair
Angiogenesis in Models Relevant for Bone Regeneration and Osteosarcoma via Reduction of VEGF and
SDF-1. Mar. Drugs 2017, 15, 186. [CrossRef] [PubMed]
81. Hwang, P.-A.; Hung, Y.-L.; Phan, N.N.; Hieu, B.-T.-N.; Chang, P.-M.; Li, K.-L.; Lin, Y.-C. The in vitro and
in vivo effects of the low molecular weight fucoidan on the bone osteogenic differentiation properties.
Cytotechnology 2016, 68, 1349–1359. [CrossRef] [PubMed]
82. Kim, B.S.; Kang, H.-J.; Park, J.-Y.; Lee, J. Fucoidan promotes osteoblast differentiation via JNK- and
ERK-dependent BMP2-Smad 1/5/8 signaling in human mesenchymal stem cells. Exp. Mol. Med. 2015, 47,
e128. [CrossRef] [PubMed]
83. Uchiyama, S.; Hashizume, M.; Hokari, Y.; Nakagawa, T.; Igarashi, A.; Yamaguchi, M. Characterization
of Active Component in Marine Alga Sargassum horneri Extract in Stimulating Bone Calcification in Vitro.
J. Health Sci. 2004, 50, 634–639. [CrossRef]
84. Uchiyama, S.; Yamaguchi, M. Anabolic Effect of Marine Alga Sargassum Horneri Extract on Bone
Components in the Femoral-diaphyseal and -metaphyseal Tissues of Young and Aged Rats in Vivo.
J. Health Sci. 2002, 48, 325–330. [CrossRef]
85. Uchiyama, S.; Yamaguchi, M. Preventive Effect of Marine Alga Sargassum Horneri Extract on Bone Loss in
Streptozotocin-Diabetic Rats in Vivo. J. Health Sci. 2003, 49, 149–155. [CrossRef]
86. Matsumoto, T.; Hokari, Y.; Hashizume, M.; Yamaguchi, M. Effect of Sargassum horneri Extract on Circulating
Bone Metabolic Markers: Supplemental Intake Has an Effect in Healthy Humans. J. Health Sci. 2008, 54,
50–55. [CrossRef]
87. Das, S.K.; Ren, R.; Hashimoto, T.; Kanazawa, K. Fucoxanthin Induces Apoptosis in Osteoclast-like Cells
Differentiated from RAW264.7 Cells. J. Agric. Food Chem. 2010, 58, 6090–6095. [CrossRef] [PubMed]
88. Carson, M.A.; Nelson, J.; Cancela, M.L.; Laizé, V.; Gavaia, P.J.; Rae, M.; Heesch, S.; Verzin, E.; Maggs, C.;
Gilmore, B.F.; et al. Red algal extracts from Plocamium lyngbyanum and Ceramium secundatum stimulate
osteogenic activities in vitro and bone growth in zebrafish larvae. Sci. Rep. 2018, 8, 7725. [CrossRef]
[PubMed]
89. Tarasco, M.; Laizé, V.; Cardeira, J.; Cancela, M.L.; Gavaia, P.J. The zebrafish operculum: A powerful system to
assess osteogenic bioactivities of molecules with pharmacological and toxicological relevance. Comp. Biochem.
Physiol. Part C Toxicol. Pharmacol. 2017, 197, 45–52. [CrossRef] [PubMed]
90. Yamaguchi, K.; Yada, M.; Tsuji, T.; Kuramoto, M.; Uemura, D. Suppressive Effect of Norzoanthamine
Hydrochloride on Experimental Osteoporosis in Ovariectomized Mice. Biol. Pharm. Bull. 1999, 22, 920–924.
[CrossRef] [PubMed]
91. Akakabe, M.; Kumagai, K.; Tsuda, M.; Konishi, Y.; Tominaga, A.; Tsuda, M.; Fukushi, E.; Kawabata, J.
Amphirionin-5, a novel linear polyketide from a cultured marine dinoflagellate Amphidinium species with a
potent cell proliferation-promoting activity. Tetrahedron Lett. 2014, 55, 3491–3494. [CrossRef]
92. Lee, K.; Silva, E.A.; Mooney, D.J. Growth factor delivery-based tissue engineering: General approaches and a
review of recent developments. J. R. Soc. Interface 2011, 8, 153–170. [CrossRef] [PubMed]
93. Rogers, A.D. The biology of Lophelia pertusa (Linnaeus 1758) and other deep-water reef-forming corals and
impacts from human activities. Int. Rev. Hydrobiol. 1999, 84, 315–406. [CrossRef]
94. Goffredo, S.; Vergni, P.; Reggi, M.; Caroselli, E.; Sparla, F.; Levy, O.; Dubinsky, Z.; Falini, G. The skeletal
organic matrix from Mediterranean coral Balanophyllia europaea influences calcium carbonate precipitation.
PLoS ONE 2011, 6, e22338. [CrossRef] [PubMed]
95. Zoccola, D.; Moya, A.; Béranger, G.E.; Tambutté, E.; Allemand, D.; Carle, G.F.; Tambutté, S. Specific expression
of BMP2/4 ortholog in biomineralizing tissues of corals and action on mouse BMP receptor. Mar. Biotechnol.
2009, 11, 260. [CrossRef] [PubMed]
96. Kramarsky-Winter, E.; Loya, Y. Tissue regeneration in the coral Fungia granulosa: The effect of extrinsic and
intrinsic factors. Mar. Biol. 2000, 137, 867–873. [CrossRef]
Mar. Drugs 2018, 16, 340 16 of 16
97. Hughes, T.P.; Graham, N.A.J.; Jackson, J.B.C.; Mumby, P.J.; Steneck, R.S. Rising to the challenge of sustaining
coral reef resilience. Trends Ecol. Evol. 2010, 25, 633–642. [CrossRef] [PubMed]
98. Harriott, V.J. Can corals be harvested sustainably? Ambio 2003, 32, 130–133. [CrossRef] [PubMed]
99. Proksch, P.; Edrada-Ebel, R.; Ebel, R. Drugs from the Sea—Opportunities and Obstacles. Mar. Drugs 2003, 1,
5–17. [CrossRef]
100. Singh, A.; Nigam, P.S.; Murphy, J.D. Mechanism and challenges in commercialisation of algal biofuels.
Bioresour. Technol. 2011, 102, 26–34. [CrossRef] [PubMed]
101. Saltonstall, K. Cryptic invasion by a non-native genotype of the common reed, Phragmites australis, into
North America. Proc. Natl. Acad. Sci. USA 2002, 99, 2445–2449. [CrossRef] [PubMed]
102. Christensen, K.; Doblhammer, G.; Rau, R.; Vaupel, J.W. Ageing populations: The challenges ahead. Lancet
2009, 374, 1196–1208. [CrossRef]
© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
